| Lana Alexander, MA, CCC-SLP | |
|
850 Hungerford Dr, Rockville, MD 20850 | |
| (240) 740-5500 | |
| Not Available |
| Full Name | Lana Alexander |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 850 Hungerford Dr, Rockville, Maryland |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043463409 | NPI | - | NPPES |
| 006450000 | Medicaid | FL |
| Provider Name | Speech & Language Rehab Services Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1093459554 PECOS PAC ID: 6204281025 Enrollment ID: O20231016000455 |
News Archive
Democratic leaders were jubilant that the nonpartisan Congressional Budget Office determined that the Senate bill would cut federal deficits by $130 billion over the next decade. That projection, released shortly before midnight Wednesday, represents the biggest cost savings of any legislation to come before the House or Senate this year, but the measure's effective date also was pushed back by one year, to 2014.
Amorcyte, Inc., a biopharmaceutical company developing cell therapy products to treat cardiovascular disease, today announced that it has been granted United States Patent number 7,794,705 titled "Compositions and Methods of Vascular Injury Repair." The patent contains both composition of matter and method claims surrounding therapeutic chemotactic hematopoietic stem cell products used in treating or repairing a vascular injury following an acute myocardial infarction (AMI), and delivery of the cell therapy.
Over a quarter of UK patients treated for growth hormone-producing tumours do not achieve 'safe' growth hormone levels, according to a 30 year UK multi-centre study of clinical management of the rare disease acromegaly. The findings by the Society for Endocrinology UK Acromegaly Register, published in the November issue of Clinical Endocrinology, show that drugs to control acromegaly often fail to bring the disease completely under control in routine clinical practice.
Shire plc, the global specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has granted marketing approval for VPRIV, a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of Type 1 Gaucher disease in pediatric and adult patients.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lana Alexander, MA, CCC-SLP 850 Hungerford Dr, Rockville, MD 20850-1718 Ph: (240) 740-5500 | Lana Alexander, MA, CCC-SLP 850 Hungerford Dr, Rockville, MD 20850 Ph: (240) 740-5500 |
News Archive
Democratic leaders were jubilant that the nonpartisan Congressional Budget Office determined that the Senate bill would cut federal deficits by $130 billion over the next decade. That projection, released shortly before midnight Wednesday, represents the biggest cost savings of any legislation to come before the House or Senate this year, but the measure's effective date also was pushed back by one year, to 2014.
Amorcyte, Inc., a biopharmaceutical company developing cell therapy products to treat cardiovascular disease, today announced that it has been granted United States Patent number 7,794,705 titled "Compositions and Methods of Vascular Injury Repair." The patent contains both composition of matter and method claims surrounding therapeutic chemotactic hematopoietic stem cell products used in treating or repairing a vascular injury following an acute myocardial infarction (AMI), and delivery of the cell therapy.
Over a quarter of UK patients treated for growth hormone-producing tumours do not achieve 'safe' growth hormone levels, according to a 30 year UK multi-centre study of clinical management of the rare disease acromegaly. The findings by the Society for Endocrinology UK Acromegaly Register, published in the November issue of Clinical Endocrinology, show that drugs to control acromegaly often fail to bring the disease completely under control in routine clinical practice.
Shire plc, the global specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has granted marketing approval for VPRIV, a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of Type 1 Gaucher disease in pediatric and adult patients.
› Verified 9 days ago
Ms. Emily Dayle Quinn, M.S. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5801 Nicholson Ln, Apt 1623, Rockville, MD 20852 Phone: 215-272-5003 | |
Catherine Penny, MA Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9975 Medical Center Dr, Rockville, MD 20850 Phone: 301-738-9691 | |
Julia Migliorini, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9975 Medical Center Dr, Rockville, MD 20850 Phone: 301-738-9691 | |
Monica D Churm, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1401 Rockville Pike, Rockville, MD 20852 Phone: 301-947-6058 | |
Nicole Wyche, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9975 Medical Center Dr, Rockville, MD 20850 Phone: 301-738-9691 | |
Diane Greenfeld Flynn, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4511 Bestor Dr, Rockville, MD 20853 Phone: 240-740-2150 Fax: 301-871-0950 | |
Melissa Weiner, M.S. CCC-SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 15245 Shady Grove Rd, Rockville, MD 20850 Phone: 301-208-3210 |